Last reviewed · How we verify
ivosidenib and nivolumab
ivosidenib and nivolumab is a Small molecule drug developed by Jason J. Luke, MD. It is currently in Phase 2 development.
At a glance
| Generic name | ivosidenib and nivolumab |
|---|---|
| Sponsor | Jason J. Luke, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma (PHASE1, PHASE2)
- Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (PHASE2)
- A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ivosidenib and nivolumab CI brief — competitive landscape report
- ivosidenib and nivolumab updates RSS · CI watch RSS
- Jason J. Luke, MD portfolio CI
Frequently asked questions about ivosidenib and nivolumab
What is ivosidenib and nivolumab?
ivosidenib and nivolumab is a Small molecule drug developed by Jason J. Luke, MD.
Who makes ivosidenib and nivolumab?
ivosidenib and nivolumab is developed by Jason J. Luke, MD (see full Jason J. Luke, MD pipeline at /company/jason-j-luke-md).
What development phase is ivosidenib and nivolumab in?
ivosidenib and nivolumab is in Phase 2.
Related
- Manufacturer: Jason J. Luke, MD — full pipeline
- Compare: ivosidenib and nivolumab vs similar drugs
- Pricing: ivosidenib and nivolumab cost, discount & access